Research Suggests New Treatment Strategy for Deadly Metastatic Cancer
The ability of lung tumor cells to spread rapidly within the body makes lung cancer difficult to eradicate and contributes to its status as the leading cause of U.S. cancer deaths in both men and women. But according to a new study led by UC San Francisco scientists, the cancer’s ability to spread may often be due to the inactivation of a single protective protein within tumor cells.
The researchers found genetic mutations in the protective protein, called Capicua (CIC), with disproportionate frequency in human lung cancers that have spread to other body sites – an event called metastasis.
Furthermore, the researchers determined that the protein could also be inactivated as a downstream consequence of common biochemical abnormalities that arise in lung cancer, even in cases where the CIC gene itself is not mutated. Some of these abnormalities, thought to drive tumor growth, are already being targeted by both FDA-approved and experimental drugs in clinical trials.
Possibility of Reactivating CIC to Stop Cancer
The new findings, published online Nov. 21, 2016, in Nature Genetics, point to the possibility of reactivating CIC to stop the spread of lung cancer, said senior study author Trever Bivona, MD, PhD, associate professor of hematology and oncology and member of the UCSF Helen Diller Family Comprehensive Cancer Center.
“We found that this protein, first discovered as a regulator of development in the fruit fly, and also known to direct normal development of air sacs in the lungs, can be co-opted by tumors and inactivated to cause cancers to spread,” Bivona said. “While there are already treatments in development that might reactivate CIC and stop metastasis, more work is needed to reveal whether such a strategy will be effective.”
The study, a collaborative effort involving scientists from several research institutions in addition to UCSF, focused on the most common lung cancer, called non-small cell lung cancer (NSCLC), the most deadly form of cancer worldwide.
Most of the laboratory experiments were conducted by the study’s first author, Ross Okimoto, MD, a UCSF medical oncologist, who took the unusual and difficult step of injecting fluorescently labeled human lung tumor cells directly into the lungs of mice used to model the disease, instead of beneath the skin or into the tail vein, as is more typical.
Using gene sequencing on three closely related human lung cancer cell lines, Okimoto determined that there were few genetic differences between two metastatic tumor cell lines and a closely related but localized tumor cell line. This work quickly led to the identification of CIC gene deletion and lack of the corresponding CIC protein as a suspect in lung cancer metastasis.
Tracking Tumor Cells as They Escaped Lung
Okimoto then monitored the metastatic potential of lung tumors in the mice by tracking fluorescently labeled tumor cells as they escaped from the lung and entered the bloodstream. He found that genetically engineering tumor cells to equip them with normal CIC gene resulted in the loss of tumors’ ability to spread.
The researchers then analyzed genetic data from hundreds of human lung cancers and found that CIC was mutated in metastatic lung cancer seven times more often than in lung tumors that had not yet spread. The same gene also is often mutated in metastatic gastric cancers, they discovered.
The scientists tested 11 different CIC mutations identified in human metastatic lung cancers in mice and found evidence that any of these mutations could be a causal factor of metastasis in the human lung cancers: specifically, none of the mutant CIC genes the researchers inserted had enough functionality to reduce the cancer’s ability to spread, as insertion of the normal CIC gene had.
The researchers also determined that CIC may be suppressed in some metastatic lung cancers even when the CIC gene is normal. They found that the MAPK signaling pathway, a biochemical pathway that includes enzymes that often are overactive in lung cancer, frequently inactivates normally functioning CIC proteins.
Whether caused by genetic mutation or MAPK pathway dysregulation, the loss of CIC releases the brakes that hold downstream proteins in check. In the mice, Okimoto determined that one of proteins held in check by CIC, called MMP24, is needed for tumors that arise in the lungs to take root at distant body sites, such as bone.
Drugs Used to FIght Tumor Growth May Prevent Spread
Drugs that block overactive MAPK signaling, including a class known as RAF-MEK-ERK inhibitors, have already been used as a way to fight tumor growth. The new discovery suggests that these drugs might also act to prevent tumor spread by preventing inactivation of CIC, said Bivona, who plans more mouse studies of these drugs to investigate their effects on cancer metastasis in more detail.
More effective lung cancer treatments are needed to improve outcomes for patients, Bivona said, as fewer than one-in-five patients diagnosed with NSCLC remains alive five years later. The unfavorable odds are due in part to most cases being diagnosed after the cancer already has metastasized.
Additional authors of the Nature Genetics study are Victor R. Olivas, Wei Wu, PhD, Beatrice Gini, PhD, Saurabh Asthana, PhD, Gorjan Hrustanovic, PhD, Jennifer Flanagan, Asmin Tulpule, MD, PhD, and Collin M. Blakely, MD, PhD from UCSF; Frank Breitenbuecher, PhD and Martin Schuler, MD, from the West German Cancer Center at University Hospital Essen, Essen, Germany; Matan Hofree, PhD, of the Broad Institute of MIT and Harvard and the Dana-Farber Cancer Institute; Henry J. Haringsma and Andrew D. Simmons, PhD, of Clovis Oncology Inc., San Francisco; and Kyle Gowen, James Suh, MD, Vincent Miller, MD, and Siraj Ali, MD, PhD, from Foundation Medicine, Cambridge, Massachusetts.
The research was funded by a National Institutes of Health Director’s New Innovator Award to Bivona, and by a fellowship from the A.P. Giannini Foundation to Okimoto.
UC San Francisco (UCSF) is a leading university dedicated to promoting health worldwide through advanced biomedical research, graduate-level education in the life sciences and health professions, and excellence in patient care. It includes top-ranked graduate schools of dentistry, medicine, nursing and pharmacy; a graduate division with nationally renowned programs in basic, biomedical, translational and population sciences; and a preeminent biomedical research enterprise. It also includes UCSF Health, which comprises three top-ranked hospitals, UCSF Medical Center and UCSF Benioff Children’s Hospitals in San Francisco and Oakland, and other partner and affiliated hospitals and healthcare providers throughout the Bay Area.